Subscribe To
RAPT / RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
RAPT News
By Seeking Alpha
June 13, 2023
RAPT Therapeutics: Major Catalysts Are A Long Way Off
RAPT Therapeutics has solid data from early trials but has a habit of going down on good data. One reason could be that the stock is heavily instituti more_horizontal
By Seeking Alpha
March 30, 2023
RAPT Therapeutics: Potential Strong Upside Ahead
RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modulate the critical immune drivers of inflammator more_horizontal
By Zacks Investment Research
February 10, 2023
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet
The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not more_horizontal
By Zacks Investment Research
January 25, 2023
Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)
Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the mov more_horizontal
By GlobeNewsWire
November 30, 2022
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s more_horizontal
By Zacks Investment Research
November 22, 2022
Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick
RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well. more_horizontal